Plain-English translation of NCT06341426 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Major Depressive Disorder research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing psilocybin—a psychedelic compound—combined with specialized psychotherapy to treat depression that has not responded to at least two standard antidepressants. The study will compare whether taking the medication once is as effective as taking it twice, to figure out the best dose for future patients. Each dosing session includes 6–8 hours of one-on-one support from two trained therapists.
Many people with severe depression do not get better with standard medications, leaving them without effective options. Early research suggests this medication combined with therapy may help, but doctors don't yet know if one dose or two doses works best—and whether giving a second dose is worth the extra time, cost, and potential side effects.
If you join, you will be randomly assigned to receive either one or two doses of the medication paired with psychotherapy. Each dosing day involves spending 6–8 hours at the research clinic with two therapists supporting you through the experience. You'll have preparation sessions before the dose and integration sessions afterward to help process your experience. The study lasts 8 weeks, and researchers will monitor your mood, safety, and any side effects throughout, with special attention to your blood pressure and mental state during dosing days.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
Canada